Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleTOXICOLOGY

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

Olga Popelová, Martin Štěrba, Tomáš Šimůnek, Yvona Mazurová, Ivana Gunčová, Miloš Hroch, Michaela Adamcová and Vladimír Geršl
Journal of Pharmacology and Experimental Therapeutics July 2008, 326 (1) 259-269; DOI: https://doi.org/10.1124/jpet.108.137604
Olga Popelová
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Štěrba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomáš Šimůnek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvona Mazurová
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivana Gunčová
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miloš Hroch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Adamcová
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimír Geršl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Anthracycline cardiotoxicity ranks among the most severe complications of cancer chemotherapy. Although its pathogenesis is only incompletely understood, “reactive oxygen species (ROS) and iron” hypothesis has gained the widest acceptance. Besides dexrazoxane, novel oral iron chelator deferiprone has been recently reported to afford significant cardioprotection in both in vitro and ex vivo conditions. Therefore, the aim of this study was to assess whether deferiprone 1) has any effect on the anticancer action of daunorubicin and 2) whether it can overcome or significantly reduce the chronic anthracycline cardiotoxicity in the in vivo rabbit model (daunorubicin, 3 mg/kg i.v., weekly for 10 weeks). First, using the leukemic cell line, deferiprone (1–300 μM) was shown not to blunt the antiproliferative effect of daunorubicin. Instead, in clinically relevant concentrations (>10 μM), deferiprone augmented the antiproliferative action of daunorubicin. However, deferiprone (10 or 50 mg/kg administered p.o. before each daunorubicin dose) failed to afford significant protection against daunorubicin-induced mortality, left ventricular lipoperoxidation, cardiac dysfunction, and morphological cardiac deteriorations, as well as an increase in plasma cardiac troponin T. Hence, this first in vivo study changes the current view on deferiprone as a potential cardioprotectant against anthracycline cardiotoxicity. In addition, these results, together with our previous findings, further suggest that the role of iron and its chelation in anthracycline cardiotoxicity is not as trivial as originally believed and/or other mechanisms unrelated to iron-catalyzed ROS production are involved.

Footnotes

  • This study was supported by the Charles University in Prague (Grant 89/2006/C) and the Czech Ministry of Education, Youth and Sports (Research Project MSM0021620820).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.108.137604.

  • ABBREVIATIONS: DAU, daunorubicin; L1, deferiprone; ROS, reactive oxygen species; ICRF-187, dexrazoxane; cTnT, concentration of troponin T; ICL670, deferasirox; MDA, malondialdehyde; LV, left ventricular; FS, fractional shortening; ANOVA, analysis of variance; ADR-925, N,N′-[(1S)-1-methyl-1,2-ethanediyl]bis[N-(2-amino-2-oxoethyl)glycine].

    • Received February 5, 2008.
    • Accepted April 22, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleTOXICOLOGY

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

Olga Popelová, Martin Štěrba, Tomáš Šimůnek, Yvona Mazurová, Ivana Gunčová, Miloš Hroch, Michaela Adamcová and Vladimír Geršl
Journal of Pharmacology and Experimental Therapeutics July 1, 2008, 326 (1) 259-269; DOI: https://doi.org/10.1124/jpet.108.137604

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleTOXICOLOGY

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

Olga Popelová, Martin Štěrba, Tomáš Šimůnek, Yvona Mazurová, Ivana Gunčová, Miloš Hroch, Michaela Adamcová and Vladimír Geršl
Journal of Pharmacology and Experimental Therapeutics July 1, 2008, 326 (1) 259-269; DOI: https://doi.org/10.1124/jpet.108.137604
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Chemoproteomics Investigation of Testicular Toxicity with BTK Inhibitor
  • Bosentan Alters Bile Salt Disposition
  • Off-Target Deactivation of PDE6 by VCP Inhibitor CB-5083
Show more Toxicology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics